Identification of Breast Tumor Mutations in BRCA1 That Abolish Its Function in Homologous DNA Recombination

Overview

Journal Cancer Res

Specialty Oncology

Date 2010 Jan 28

PMID 20103620

Citations 81

Authors

Derek J R Ransburgh

Natsuko Chiba

Chikashi Ishioka

Amanda Ewart Toland

Jeffrey D Parvin

Affiliations

Soon will be listed here.

Abstract

Effects of breast cancer-associated gene 1 (BRCA1) missense mutations on the function of BRCA1 protein in DNA recombination have been little studied. In this report, we adapted a homology-directed recombination (HDR) assay to analyze the effects of BRCA1 mutations on this function. Using a HeLa-derived cell line with a genomically integrated recombination substrate, we expressed an endonuclease creating a double-stranded break in the substrate that the HDR assay scores by generation of green fluorescent protein-positive cells. By combining RNA interference (RNAi) that targets cellular BRCA1 mRNA with expression of RNAi-resistant BRCA1 mutants, we could effectively substitute selected point mutants to test these in the cellular recombination assay. We found that approximately 300 residues at both termini of the BRCA1 protein were essential for HDR. Whereas some mutations analyzed were neutral, mutations that altered any zinc-coordinating residue or generated M18T and T37R alterations were defective for recombination. This study established a robust assay system to analyze the function of BRCA1 in regulating homologous recombination, which is critical for its tumor suppressor function.

Citing Articles

Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

Moser S, Jonkers J Cancer Discov. 2025; 15(3):461-480.

PMID: 40025950 PMC: 11893084. DOI: 10.1158/2159-8290.CD-24-1326.

Structural and functional prediction, evaluation, and validation in the post-sequencing era.

Li C, Luo Y, Xie Y, Zhang Z, Liu Y, Zou L Comput Struct Biotechnol J. 2024; 23:446-451.

PMID: 38223342 PMC: 10787220. DOI: 10.1016/j.csbj.2023.12.031.

Functional assay for assessment of pathogenicity of BAP1 variants.

Repo P, Backlund M, Kivela T, Turunen J Hum Mol Genet. 2023; 33(5):426-434.

PMID: 37956408 PMC: 10877462. DOI: 10.1093/hmg/ddad193.

Crucial roles of the BRCA1-BARD1 E3 ubiquitin ligase activity in homology-directed DNA repair.

Wang M, Li W, Tomimatsu N, Yu C, Ji J, Alejo S Mol Cell. 2023; 83(20):3679-3691.e8.

PMID: 37797621 PMC: 10591799. DOI: 10.1016/j.molcel.2023.09.015.

Integrating deep mutational scanning and low-throughput mutagenesis data to predict the impact of amino acid variants.

Fu Y, Bedo J, Papenfuss A, Rubin A Gigascience. 2023; 12.

PMID: 37721410 PMC: 10506130. DOI: 10.1093/gigascience/giad073.

References

Couch F, Rasmussen L, Hofstra R, Monteiro A, Greenblatt M, de Wind N . Assessment of functional effects of unclassified genetic variants. Hum Mutat. 2008; 29(11):1314-26. PMC: 2771414. DOI: 10.1002/humu.20899. View

Sweet K, Senter L, Pilarski R, Wei L, Toland A . Characterization of BRCA1 ring finger variants of uncertain significance. Breast Cancer Res Treat. 2009; 119(3):737-43. PMC: 4283813. DOI: 10.1007/s10549-009-0438-6. View

Vega A, Campos B, Bond P, Janin N, Douglas F, Domenech M . The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat. 2001; 17(6):520-1. DOI: 10.1002/humu.1136. View

Moynahan M, Pierce A, Jasin M . BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001; 7(2):263-72. DOI: 10.1016/s1097-2765(01)00174-5. View

Pierce A, Hu P, Han M, Ellis N, Jasin M . Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cells. Genes Dev. 2001; 15(24):3237-42. PMC: 312854. DOI: 10.1101/gad.946401. View

Moynahan M, Chiu J, Koller B, Jasin M . Brca1 controls homology-directed DNA repair. Mol Cell. 1999; 4(4):511-8. DOI: 10.1016/s1097-2765(00)80202-6. View

Sankaran S, Starita L, Simons A, Parvin J . Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function. Cancer Res. 2006; 66(8):4100-7. DOI: 10.1158/0008-5472.CAN-05-4430. View

Miki Y, Swensen J, Futreal P, Harshman K, Tavtigian S, Liu Q . A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266(5182):66-71. DOI: 10.1126/science.7545954. View

Nakanishi A, Han X, Saito H, Taguchi K, Ohta Y, Imajoh-Ohmi S . Interference with BRCA2, which localizes to the centrosome during S and early M phase, leads to abnormal nuclear division. Biochem Biophys Res Commun. 2007; 355(1):34-40. DOI: 10.1016/j.bbrc.2007.01.100. View

10.

Morris J, Pangon L, Boutell C, Katagiri T, Keep N, Solomon E . Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet. 2006; 15(4):599-606. DOI: 10.1093/hmg/ddi476. View

11.

Friedman L, Ostermeyer E, Szabo C, Dowd P, Lynch E, Rowell S . Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet. 1994; 8(4):399-404. DOI: 10.1038/ng1294-399. View

12.

Easton D, Deffenbaugh A, Pruss D, Frye C, Wenstrup R, Allen-Brady K . A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007; 81(5):873-83. PMC: 2265654. DOI: 10.1086/521032. View

13.

Snouwaert J, Gowen L, Latour A, Mohn A, Xiao A, Dibiase L . BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. Oncogene. 2000; 18(55):7900-7. DOI: 10.1038/sj.onc.1203334. View

14.

Reid L, Shakya R, Modi A, Lokshin M, Cheng J, Jasin M . E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks. Proc Natl Acad Sci U S A. 2008; 105(52):20876-81. PMC: 2603436. DOI: 10.1073/pnas.0811203106. View

15.

Carvalho M, Marsillac S, Karchin R, Manoukian S, Grist S, Swaby R . Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res. 2007; 67(4):1494-501. PMC: 2936786. DOI: 10.1158/0008-5472.CAN-06-3297. View

16.

Laufer M, Nandula S, Modi A, Wang S, Jasin M, Murty V . Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair. J Biol Chem. 2007; 282(47):34325-33. DOI: 10.1074/jbc.M705198200. View

17.

Spearman A, Sweet K, Zhou X, McLennan J, Couch F, Toland A . Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol. 2008; 26(33):5393-400. PMC: 2651073. DOI: 10.1200/JCO.2008.17.8228. View

18.

Starita L, Horwitz A, Keogh M, Ishioka C, Parvin J, Chiba N . BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J Biol Chem. 2005; 280(26):24498-505. DOI: 10.1074/jbc.M414020200. View

19.

Anderson S, Schlegel B, Nakajima T, Wolpin E, Parvin J . BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat Genet. 1998; 19(3):254-6. DOI: 10.1038/930. View

20.

Brzovic P, Rajagopal P, Hoyt D, King M, Klevit R . Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol. 2001; 8(10):833-7. DOI: 10.1038/nsb1001-833. View